Promethera acquires Baliopharm

The Belgium-based cell therapy company Promethera Biosciences SA has branched out into biologics with the acquisition of Baliopharm AG, a Swiss developer of therapies for immune-mediated inflammatory diseases and cancer. Financial details of the transaction were not disclosed.

Full text available to subscribers only. Click here for information on subscribing to MedNous.